Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
8 minute read

Veterans With ALS Who Support Co’s Request For The FDA To Hold A Public Advisory Committee Meeting To Engage In Scientific Discourse About The “Clinically Meaningful” Evidence Supporting FDA’s Approval Of A Mesenchymal Stem Cell Therapy, NurOwn

By Benzinga Newsdesk
November 23, 3:52 PM
Veterans have a Significantly Increased Risk of 100% Fatal ALS, Caused by their Service for our Country FDA Advisory Committee Meeting is Essential to Allow Veterans' Voices to be Heard about Need for

BCLI

Read More
1 minute read

AbbVie Earlier Announced European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn’s Disease

By Charles Gross
November 23, 6:48 AM
AbbVie (NYSE: ABBV) announced the European Commission (EC) approved SKYRIZI® (risankizumab, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had in

ABBV

Read More
3 minute read

Reported Late Tuesday, Mesoblast Announces Top-Line Long-Term Survival Results For Remestemcel-L From Its Pivotal Phase 3 Trial Through 4-Years In Children With Steroid-Refractory Acute Graft vs Host Disease

By Benzinga Newsdesk
November 23, 2:05 AM
Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001 Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in

MESO